- CEO Dr. Sudhir Srivastava, in a recent interview with The Motley Fool , that SS Innovations has performed more than 15,000 procedures using its SSi Mantra robotic surgical systems, including approximately 750 cardiac procedures.
- In addition, more than 200 telesurgeries have been performed using the platform, including 27 cardiac procedures, as the company explores ways to extend specialist surgical expertise to underserved communities.
- Srivastava highlighted the SSi Mantra’s differentiated engineering, including its 4K 3D visualization, surgeon-controlled anatomical imaging and modular design supporting up to five robotic arms.
- SS Innovations is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, with the objective of bringing additional production capabilities in-house.
- Regulatory applications in Europe and the United States are also progressing, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers.
- The company is experiencing strong commercial momentum, with first-half 2026 revenue increasing approximately 66% year-over-year to about $25 million.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is seeing increased adoption of its SSi Mantra surgical robotic platform, with CEO Dr. Sudhir Srivastava telling The Motley Fool’s interviewer Rachel Warren that the company’s commercial growth reflects a combination of technological capabilities, clinical experience and affordability (https://ibn.fm/EJk05).
During the interview, Srivastava said the company had performed more than 15,000 procedures using its robotic systems, including approximately 750 cardiac surgeries. He also highlighted the platform’s expanding use across multiple surgical specialties, emphasizing that the SSi Mantra should not be viewed exclusively as a cardiac surgery robot.
The company’s first-half 2026 financial performance provides additional context for that expansion. Revenue increased approximately 66% year over year to about $25 million, according to figures discussed during the interview. Asked what was driving the growth, Srivastava pointed to increasing hospital adoption and the platform’s ability to perform procedures across a broad range of specialties. He argued that hospitals are increasingly questioning why they should pay substantially more for competing systems when comparable capabilities may be available at a lower cost. He also emphasized the company’s relatively rapid development process, saying its engineering team can move from decisions to new product development within months rather than years.
A substantial part of the discussion focused on the engineering philosophy behind the SSi Mantra. Srivastava explained that he wanted to develop a system that differed from conventional robotic platforms, with particular attention to the surgeon’s working environment and the needs of the wider operating-room team.
The surgeon command center features a 32-inch 4K three-dimensional display designed to provide depth perception without requiring surgeons to work in a hunched position. A separate 23-inch touchscreen allows surgeons to access patient imaging, including CT scans, MRI scans and angiograms.
Srivastava also described proprietary software that converts DICOM medical images into three-dimensional anatomical models. Surgeons can manipulate these models, examine anatomical structures and review patient-specific information through the touchscreen. Another feature is the system’s magnetic sensor-based hand controls, which he said provide accurate movement with low latency and a larger working area. The SSi Mantra’s modular configuration allows hospitals to use three, four or five robotic arms. According to Srivastava, the surgeon can control all five arms from the same command center.
He also highlighted the system’s separate vision cart, which provides the operating-room team with the same 3D view available to the surgeon. He said this feature is intended to improve coordination between the surgeon and the bedside team, while supporting training and reducing the potential for instrument-related errors.
One of the most extensive portions of the interview concerned telesurgery, an area in which Srivastava sees considerable potential for the company’s technology. He reported that SS Innovations had completed more than 200 telesurgeries, including 27 cardiac procedures. He described a cardiac operation performed across approximately 10,000 kilometers, with the surgeon operating from Barcelona and the patient located near Bangalore.
Srivastava also recalled an earlier initiative in which 24 telesurgeries were conducted in a single day from the company’s office in India. The procedures involved nine surgeons and four robotic systems, including four cardiac cases.
Srivastava believes remote surgical capabilities could help address the uneven distribution of specialist medical expertise, particularly in smaller cities and communities where patients may otherwise need to travel considerable distances for treatment. He described this approach as decentralizing access to surgery, allowing experienced surgeons to provide assistance remotely through teleproctoring and, where authorized, take control of a procedure when necessary.
Srivastava also discussed the company’s MantrAsana independent tele-surgeon console. He said the chair-based system allows surgeons to operate remotely without occupying a conventional operating-room console. He recalled performing a cardiac procedure from his living room using a separate fiber connection.
India remains SS Innovations’ largest market. Srivastava said the company had installed more than 245 systems overall, with approximately 220 located in India and the remainder distributed across other countries. He highlighted the geographic distribution of those installations, saying nearly 70% of the Indian systems were located in tier-two and tier-three cities. According to Srivastava, these are locations where hospitals might previously have considered robotic surgery financially inaccessible. He attributed adoption to the combination of system performance and a more affordable purchasing proposition.
The company’s commercial model includes outright capital sales, deferred payment arrangements, leasing and pay-per-use agreements. Srivastava estimated that capital purchases represented approximately 60% of sales, with deferred payments accounting for another 20%. Recurring revenue is also generated through surgical instruments, consumables and service agreements. He expects these contributions to increase as the installed base grows and hospitals perform more procedures.
Srivastava said the SSi Mantra is designed and manufactured in India, with the company currently outsourcing certain components while retaining responsibility for software development, final integration and testing. To support anticipated growth, SS Innovations has signed a memorandum of understanding involving approximately 10 acres of land in a neighboring Indian state. The planned manufacturing facility is intended to expand production capacity and bring additional machine tooling and CNC manufacturing capabilities in-house. He said the objective is to establish the facility within the next year to 18 months, improving quality control and reducing production costs and supply-chain exposure.
Artificial intelligence is another development priority. Srivastava described applications that automatically collect surgical data, including console time and the duration of individual procedural steps. The information can support research, surgeon training and the evaluation of surgical techniques. He also discussed early semi-automated capabilities, in which recorded movements can be repeated by the robotic system under controlled conditions. He stressed that the surgeon remains in control, with automation intended to assist rather than replace clinical judgment.
International expansion remains a central objective. Srivastava said European regulatory applications were progressing, with responses to additional questions recently submitted. He expressed hope for European approval in the first quarter of 2027, while acknowledging that regulatory timelines cannot be guaranteed.
For the United States, the company intends to pursue a direct-sales strategy and build its own commercial team. Srivastava identified ambulatory surgery centers as a potential market, noting that many procedures could be performed using the system’s three-arm configuration, potentially making robotic surgery more accessible to smaller facilities.
Looking three to five years ahead, Srivastava said he wants SS Innovations to develop into a broader digital medical technology company rather than remain solely a surgical robotics manufacturer. He indicated that additional products and regulatory initiatives are in development, although he declined to discuss specific projects during the interview.
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
